Items tagged with Medicines
HIV i-Base/TAG: 2015 Pipeline Report (post with simple image)
Latest annual review on HIV, HCV and TB drugs, diagnostics, vaccines, preventive technologies, research toward a cure, and immune-based and gene therapies in development.
Tuberculosis in adults and children (post with simple image)
A monograph written for healthcare workers in any setting who are faced with the complex care for patients with tuberculosis.
Appeal to develop VXc-486 for tuberculosis (post with simple image)
Advocates urge Vertex to assure the timely and responsible development of drug candidate VXc-486 for tuberculosis.
Life-saving drug stopped by sole supplier (post with simple image)
South Africa is running out of an essential medicine for treating very sick patients with tuberculosis (TB) and drug-resistant bacterial infections. Many hospitals are already out of stock.
Intravenous rifampicin reintroduced in South Africa (post with simple image)
Equity Pharmaceuticals is the new supplier of the drug.
TB Alliance and partners announce world’s first availability of appropriate, child-friendly TB medicines in correct doses (post with simple image)
Medication simplifies and improves treatment for 1 million children with TB; Medicines come in dispersible fixed-dose combinations at the correct dosages, tablets no longer need to be cut or crushed; These products can improve adherence and child survival from TB.
Sanofi launches new Priftin® (rifapentine) packaging (post with simple image)
BRIDGEWATER, N.J., Dec. 1, 2015 -- Sanofi announced today the launch of a new 24-count tablet pack of Priftin® (rifapentine) for the treatment of latent tuberculosis infection (LTBI) in patients two years of age and older who are at high risk of progression to tuberculosis (TB) disease. The new 24-count package is tailored for use in the treatment of LTBI and represents one month of Priftin for most patients. The new 24-count packaging features individual tablet printing on the backing foil with individually perforated tablet blisters, and has an extended shelf-life of up to three years.
Phase 1 clinical trial of TB drug candidate TBA-354 discontinued (post with simple image)
More investment is needed to expand the portfolio of new TB drug candidates.
Advocates commend Johns Hopkins University for pursuing a public health driven path for sutezolid’s development (post with simple image)
TB advocates congratulate Johns Hopkins University’s decision to enter negotiations with the Medicines Patent Pool regarding the licensing of worldwide non-exclusive rights to sutezolid.
Page 10 of 12 · Total posts: 0←First 9 10 11 Last→